pubmed· e01.org

PubMed · PMID 28754366

Conditional survival in patients with unresectable perihilar cholangiocarcinoma.

PMID 28754366Journal HPB : the official journal of the International Hepato Pancreato Biliary AssociationYear 2017Authors 13DOI 10.1016/j.hpb.2017.07.004

  • Source PubMed
  • Journal HPB : the official journal of the International Hepato Pancreato Biliary Association
  • Year 2017
  • Authors Marcia P Gaspersz; Stefan Buettner; Jeroen L A van Vugt; Eva Roos; Robert J S Coelen; Jaynee Vugts; Eric J Belt; Jeroen de Jonge; Wojciech G Polak; François E J A Willemssen; Thomas M van Gulik; Jan N M IJzermans; Bas Groot Koerkamp
  • Licence NLM/PubMed terms

Abstract

Conditional survival is the life expectancy from a point in time for a patient who has survived a specific period after presentation. The aim of the study was to estimate conditional survival for patients with unresectable perihilar cholangiocarcinoma. Patients with unresectable perihilar cholangiocarcinoma from two academic hospitals in the Netherlands between 2002 and 2012 were assessed. A multivariable Cox proportional hazards analysis was performed to identify risk factors associated with overall survival.

Survival was estimated using the Kaplan-Meier method to evaluate factors associated with overall survival. In total, 572 patients were included. Overall survival was 42% at one year and 6% at three years. The conditional chance of surviving three years was 15% at 1 year and increased to 38% at 2 years. Independent poor prognostic factors for overall survival were age ≥65 years, tumor size >3 cm on imaging, bilirubin levels (>250 μmol/L), CA19-9 level at presentation (>1000 U/ml), and suspected distant metastases on imaging.

The conditional survival of patients with and without these prognostic factors was comparable after patients survived the first two or more years. The conditional chance of surviving for patients with unresectable perihilar cholangiocarcinoma increases with time. Poor prognostic factors become less relevant once patients have survived two years.

Record details

PMID28754366
PMCIDnot held
DOI10.1016/j.hpb.2017.07.004
JournalHPB : the official journal of the International Hepato Pancreato Biliary Association
Year2017
AuthorsMarcia P Gaspersz; Stefan Buettner; Jeroen L A van Vugt; Eva Roos; Robert J S Coelen; Jaynee Vugts; Eric J Belt; Jeroen de Jonge; Wojciech G Polak; François E J A Willemssen; Thomas M van Gulik; Jan N M IJzermans; Bas Groot Koerkamp
Licencenot stated
MeSHAged; Bile Duct Neoplasms; Bilirubin; CA-19-9 Antigen; Chi-Square Distribution; Contraindications, Procedure; Female; Humans; Kaplan-Meier Estimate; Klatskin Tumor; Male; Middle Aged; Multivariate Analysis; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Tumor Burden

Source record

Open the PubMed record. This page holds the abstract and citation fields for this PMID; no PMC full text is held for it.

Source
PubMed / NLM
PMID
28754366
Rendered
2026-11-21
Completeness
abstract and citation fields